1
|
Li S, Zhang W, Liang P, Zhu M, Zheng B, Zhou W, Wang C, Zhao X. Novel variants in the CLCN4 gene associated with syndromic X-linked intellectual disability. Front Neurol 2023; 14:1096969. [PMID: 37789889 PMCID: PMC10542403 DOI: 10.3389/fneur.2023.1096969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Accepted: 08/15/2023] [Indexed: 10/05/2023] Open
Abstract
Objective The dysfunction of the CLCN4 gene can lead to X-linked intellectual disability and Raynaud-Claes syndrome (MRXSRC), characterized by severe cognitive impairment and mental disorders. This study aimed to investigate the genetic defects and clinical features of Chinese children with CLCN4 variants and explore the effect of mutant ClC-4 on the protein expression level and subcellular localization through in vitro experiments. Methods A total of 401 children with intellectual disabilities were screened for genetic variability using whole-exome sequencing (WES). Clinical data, including age, sex, perinatal conditions, and environmental exposure, were collected. Cognitive, verbal, motor, and social behavioral abilities were evaluated. Candidate variants were verified using Sanger sequencing, and their pathogenicity and conservation were analyzed using in silico prediction tools. Protein expression and localization of mutant ClC-4 were measured using Western blotting (WB) and immunofluorescence microscopy. The impact of a splice site variant was assessed with a minigene assay. Results Exome analysis identified five rare CLCN4 variants in six unrelated patients with intellectual disabilities, including two recurrent heterozygous de novo missense variants (p.D89N and p.A555V) in three female patients, and two hemizygous missense variants (p.N141S and p.R694Q) and a splicing variant (c.1390-12T > G) that are maternally inherited in three male patients. The p.N141S variant and the splicing variant c.1390-12(T > G were novel, while p.R694Q was identified in two asymptomatic heterozygous female patients. The six children with CLCN4 variants exhibited a neurodevelopmental spectrum disease characterized by intellectual disability (ID), delayed speech, autism spectrum disorders (ASD), microcephaly, hypertonia, and abnormal imaging findings. The minigene splicing result indicated that the c.1390-12T > G did not affect the splicing of CLCN4 mRNA. In vitro experiments showed that the mutant protein level and localization of mutant protein are similar to the wild type. Conclusion The study identified six probands with CLCN4 gene variants associated with X-linked ID. It expanded the gene and phenotype spectrum of CLCN4 variants. The bioinformatic analysis supported the pathogenicity of CLCN4 variants. However, these CLCN4 gene variants did not affect the ClC-4 expression levels and protein location, consistent with previous studies. Further investigations are necessary to investigate the pathogenetic mechanism.
Collapse
Affiliation(s)
- Sinan Li
- Department of Rehabilitation, Children's Hospital of Nanjing Medical University, Nanjing, China
| | - Wenxin Zhang
- Department of Rehabilitation, Children's Hospital of Nanjing Medical University, Nanjing, China
| | - Piao Liang
- Department of Rehabilitation, Children's Hospital of Nanjing Medical University, Nanjing, China
| | - Min Zhu
- Department of Rehabilitation, Children's Hospital of Nanjing Medical University, Nanjing, China
| | - Bixia Zheng
- Nanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical University, Nanjing, China
| | - Wei Zhou
- Nanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical University, Nanjing, China
| | - Chunli Wang
- Nanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical University, Nanjing, China
| | - Xiaoke Zhao
- Department of Rehabilitation, Children's Hospital of Nanjing Medical University, Nanjing, China
| |
Collapse
|
2
|
Palmer EE, Pusch M, Picollo A, Forwood C, Nguyen MH, Suckow V, Gibbons J, Hoff A, Sigfrid L, Megarbane A, Nizon M, Cogné B, Beneteau C, Alkuraya FS, Chedrawi A, Hashem MO, Stamberger H, Weckhuysen S, Vanlander A, Ceulemans B, Rajagopalan S, Nunn K, Arpin S, Raynaud M, Motter CS, Ward-Melver C, Janssens K, Meuwissen M, Beysen D, Dikow N, Grimmel M, Haack TB, Clement E, McTague A, Hunt D, Townshend S, Ward M, Richards LJ, Simons C, Costain G, Dupuis L, Mendoza-Londono R, Dudding-Byth T, Boyle J, Saunders C, Fleming E, El Chehadeh S, Spitz MA, Piton A, Gerard B, Abi Warde MT, Rea G, McKenna C, Douzgou S, Banka S, Akman C, Bain JM, Sands TT, Wilson GN, Silvertooth EJ, Miller L, Lederer D, Sachdev R, Macintosh R, Monestier O, Karadurmus D, Collins F, Carter M, Rohena L, Willemsen MH, Ockeloen CW, Pfundt R, Kroft SD, Field M, Laranjeira FER, Fortuna AM, Soares AR, Michaud V, Naudion S, Golla S, Weaver DD, Bird LM, Friedman J, Clowes V, Joss S, Pölsler L, Campeau PM, Blazo M, Bijlsma EK, Rosenfeld JA, Beetz C, Powis Z, McWalter K, Brandt T, Torti E, Mathot M, Mohammad SS, Armstrong R, Kalscheuer VM. Functional and clinical studies reveal pathophysiological complexity of CLCN4-related neurodevelopmental condition. Mol Psychiatry 2023; 28:668-697. [PMID: 36385166 PMCID: PMC9908558 DOI: 10.1038/s41380-022-01852-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 10/10/2022] [Accepted: 10/21/2022] [Indexed: 11/17/2022]
Abstract
Missense and truncating variants in the X-chromosome-linked CLCN4 gene, resulting in reduced or complete loss-of-function (LOF) of the encoded chloride/proton exchanger ClC-4, were recently demonstrated to cause a neurocognitive phenotype in both males and females. Through international clinical matchmaking and interrogation of public variant databases we assembled a database of 90 rare CLCN4 missense variants in 90 families: 41 unique and 18 recurrent variants in 49 families. For 43 families, including 22 males and 33 females, we collated detailed clinical and segregation data. To confirm causality of variants and to obtain insight into disease mechanisms, we investigated the effect on electrophysiological properties of 59 of the variants in Xenopus oocytes using extended voltage and pH ranges. Detailed analyses revealed new pathophysiological mechanisms: 25% (15/59) of variants demonstrated LOF, characterized by a "shift" of the voltage-dependent activation to more positive voltages, and nine variants resulted in a toxic gain-of-function, associated with a disrupted gate allowing inward transport at negative voltages. Functional results were not always in line with in silico pathogenicity scores, highlighting the complexity of pathogenicity assessment for accurate genetic counselling. The complex neurocognitive and psychiatric manifestations of this condition, and hitherto under-recognized impacts on growth, gastrointestinal function, and motor control are discussed. Including published cases, we summarize features in 122 individuals from 67 families with CLCN4-related neurodevelopmental condition and suggest future research directions with the aim of improving the integrated care for individuals with this diagnosis.
Collapse
Affiliation(s)
- Elizabeth E Palmer
- Centre for Clinical Genetics, Sydney Children's Hospital Network, Randwick, NSW, Australia.
- Discipline of Paediatrics and Child Health, Faculty of Medicine and Health, University of New South Wales, Randwick, NSW, Australia.
| | | | | | - Caitlin Forwood
- Centre for Clinical Genetics, Sydney Children's Hospital Network, Randwick, NSW, Australia
| | - Matthew H Nguyen
- Discipline of Paediatrics and Child Health, Faculty of Medicine and Health, University of New South Wales, Randwick, NSW, Australia
- Department of Clinical Genetics, Liverpool Hospital, Liverpool, NSW, Australia
| | - Vanessa Suckow
- Max Planck Institute for Molecular Genetics, Group Development and Disease, Berlin, Germany
| | - Jessica Gibbons
- Max Planck Institute for Molecular Genetics, Group Development and Disease, Berlin, Germany
| | - Alva Hoff
- Istituto di Biofisica, CNR, Genova, Italy
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, 581 83, Sweden
| | - Lisa Sigfrid
- Istituto di Biofisica, CNR, Genova, Italy
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, 581 83, Sweden
| | - Andre Megarbane
- Department of Human Genetics, Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos, Lebanon
- Institut Jerome Lejeune, Paris, France
| | - Mathilde Nizon
- Service de Génétique Médicale, CHU de Nantes, Nantes Université, Nantes, France
- Nantes Université, CNRS, INSERM, l'Institut du Thorax, Nantes, France
| | - Benjamin Cogné
- Service de Génétique Médicale, CHU de Nantes, Nantes Université, Nantes, France
- Nantes Université, CNRS, INSERM, l'Institut du Thorax, Nantes, France
| | - Claire Beneteau
- Service de Génétique Médicale, CHU de Nantes, Nantes Université, Nantes, France
| | - Fowzan S Alkuraya
- Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Aziza Chedrawi
- Department of Neurosciences, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Mais O Hashem
- Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Hannah Stamberger
- Applied and Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- Neurology Department, Antwerp University Hospital, Antwerp, Belgium
| | - Sarah Weckhuysen
- Applied and Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- Neurology Department, Antwerp University Hospital, Antwerp, Belgium
- Translational Neurosciences, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium
| | - Arnaud Vanlander
- Department of Child Neurology & Metabolism, Ghent University Hospital, Ghent, Belgium
| | - Berten Ceulemans
- Department of Pediatric Neurology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
| | - Sulekha Rajagopalan
- Department of Clinical Genetics, Liverpool Hospital, Liverpool, NSW, Australia
| | - Kenneth Nunn
- Children's Hospital at Westmead, Sydney Children's Hospitals Network, Sydney, Australia
| | - Stéphanie Arpin
- Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - Martine Raynaud
- Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | | | | | - Katrien Janssens
- Center of Medical Genetics, University Hospital Antwerp/University of Antwerp, Edegem, Belgium
| | - Marije Meuwissen
- Center of Medical Genetics, University Hospital Antwerp/University of Antwerp, Edegem, Belgium
| | - Diane Beysen
- Department of Pediatric Neurology, University Hospital Antwerp/University of Antwerp, Edegem, Belgium
| | - Nicola Dikow
- Institute of Human Genetics, Heidelberg University, Heidelberg, Germany
| | - Mona Grimmel
- Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany
| | - Tobias B Haack
- Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany
| | - Emma Clement
- Department of Clinical Genetics, Great Ormond Street Hospital for Children, London, UK
| | - Amy McTague
- Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK
- Department of Neurology, Great Ormond Street Hospital, London, UK
| | - David Hunt
- Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK
| | - Sharron Townshend
- Genetic Services of WA, King Edward Memorial Hospital, Subiaco, WA, Australia
| | - Michelle Ward
- Genetic Services of WA, King Edward Memorial Hospital, Subiaco, WA, Australia
| | - Linda J Richards
- Department of Neuroscience, Washington University in St Louis School of Medicine, St Louis, MI, USA
- The University of Queensland, Queensland Brain Institute, St Lucia, QLD, Australia
| | - Cas Simons
- Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia
- Garvan Institute of Medical Research, UNSW, Sydney, NSW, Australia
| | - Gregory Costain
- Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON, Canada
| | - Lucie Dupuis
- Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON, Canada
| | - Roberto Mendoza-Londono
- Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON, Canada
| | - Tracy Dudding-Byth
- Genetics of Learning Disability Service, Newcastle, NSW, Australia
- University of Newcastle Grow Up Well Priority Research Centre, Newcastle, NSW, Australia
| | - Jackie Boyle
- Genetics of Learning Disability Service, Newcastle, NSW, Australia
| | - Carol Saunders
- Department of Pathology and Laboratory Medicine, Children's Mercy Hospital and Clinics, MI, Kansas City, USA
- Kansas City School of Medicine, University of Missouri, Kansas City, MI, USA
| | - Emily Fleming
- Division of Clinical Genetics, Children's Mercy Hospital and Clinics, Kansas City, MI, USA
| | - Salima El Chehadeh
- Service de Génétique Médicale, Institut de Génétique Médicale d'Alsace (IGMA), Hôpitaux Universitaires de Strasbourg, Strasbourg, France
- Laboratoire de Génétique Médicale, UMRS_1112, Institut de Génétique Médicale d'Alsace (IGMA), Université de Strasbourg et INSERM, Strasbourg, France
| | - Marie-Aude Spitz
- Service de Pédiatrie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Amelie Piton
- Laboratoires de Diagnostic Génétique, Institut de Génétique Médicale d'Alsace (IGMA), Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France
| | - Bénédicte Gerard
- Laboratoires de Diagnostic Génétique, Institut de Génétique Médicale d'Alsace (IGMA), Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France
| | - Marie-Thérèse Abi Warde
- Service de Pédiatrie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
- Pediatric Neurology Department, CHU de Strasbourg, Strasbourg, France
| | - Gillian Rea
- Northern Ireland Regional Genetics Service, Belfast, Northern Ireland
| | - Caoimhe McKenna
- Northern Ireland Regional Genetics Service, Belfast, Northern Ireland
| | - Sofia Douzgou
- Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway
- Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - Siddharth Banka
- Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
- Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK
| | - Cigdem Akman
- Department of Neurology, Division of Child Neurology, Columbia University Irving Medical Center, New York, USA
| | - Jennifer M Bain
- Department of Neurology, Division of Child Neurology, Columbia University Irving Medical Center, New York, USA
| | - Tristan T Sands
- Department of Neurology, Division of Child Neurology, Columbia University Irving Medical Center, New York, USA
| | - Golder N Wilson
- Texas Tech Health Sciences Center Lubbock and KinderGenome Medical Genetics, Dallas, TX, USA
| | | | | | - Damien Lederer
- Centre de Génétique Humaine, Institut de Pathologie et de Génétique ASBL, Gosselies, Belgium
| | - Rani Sachdev
- Centre for Clinical Genetics, Sydney Children's Hospital Network, Randwick, NSW, Australia
- Discipline of Paediatrics and Child Health, Faculty of Medicine and Health, University of New South Wales, Randwick, NSW, Australia
| | - Rebecca Macintosh
- Centre for Clinical Genetics, Sydney Children's Hospital Network, Randwick, NSW, Australia
- Discipline of Paediatrics and Child Health, Faculty of Medicine and Health, University of New South Wales, Randwick, NSW, Australia
| | - Olivier Monestier
- Centre de Génétique Humaine, Institut de Pathologie et de Génétique ASBL, Gosselies, Belgium
| | - Deniz Karadurmus
- Centre de Génétique Humaine, Institut de Pathologie et de Génétique ASBL, Gosselies, Belgium
| | - Felicity Collins
- Department of Medical Genomics/Clinical Genetics, Royal Prince Alfred Hospital, Camperdown, Sydney, NSW, Australia
| | - Melissa Carter
- Department of Genetics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada
| | - Luis Rohena
- Division of Medical Genetics, Department of Pediatrics, San Antonio Military Medical Center, San Antonio, TX, USA
- Department of Pediatrics, Long School of Medicine-UT Health San Antonio, San Antonio, TX, USA
| | - Marjolein H Willemsen
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Charlotte W Ockeloen
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Rolph Pfundt
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Sanne D Kroft
- Pluryn, Residential Care Setting, Groesbeek, The Netherlands
| | - Michael Field
- Genetics of Learning Disability Service, Newcastle, NSW, Australia
| | - Francisco E R Laranjeira
- Centro de Genética Médica Jacinto Magalhães, Centro Hospitalar Universitário do Porto, Porto, Portugal
| | - Ana M Fortuna
- Unit for Multidisciplinary Research in Biomedicine, School of Medicine and Biomedical Sciences, Porto University, Porto, Portugal
| | - Ana R Soares
- Unit for Multidisciplinary Research in Biomedicine, School of Medicine and Biomedical Sciences, Porto University, Porto, Portugal
| | - Vincent Michaud
- Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France
- INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, Univ., Bordeaux, France
| | - Sophie Naudion
- Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France
| | - Sailaja Golla
- Child Neurology and Neurodevelopmental Medicine Thompson Autism Center, CHOC Hospital, Orange County, CA, USA
| | - David D Weaver
- Indiana University School of Medicine, Indianapolis, USA
| | - Lynne M Bird
- University of California, San Diego, Rady Children's Hospital San Diego, San Diego, CA, USA
| | - Jennifer Friedman
- University of California, San Diego, Rady Children's Hospital San Diego, San Diego, CA, USA
| | - Virginia Clowes
- North West Thames Regional Genetics Service, London North West University Healthcare NHS Trust, Harrow, London, UK
- Imperial College London, London, UK
| | - Shelagh Joss
- West of Scotland Centre for Genomic Medicine, Queen Elizabeth University Hospital, Glasgow, UK
| | - Laura Pölsler
- Centrum Medische Genetica, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - Philippe M Campeau
- CHU Sainte-Justine Research Center, University of Montreal, Montreal, QC, Canada
| | - Maria Blazo
- Division Clinical Genetics Texas A&M University Health Science Center, College Station, TX, USA
| | - Emilia K Bijlsma
- Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands
| | - Jill A Rosenfeld
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
- Baylor Genetics Laboratories, Houston, TX, USA
| | | | - Zöe Powis
- Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA
| | | | | | | | | | - Shekeeb S Mohammad
- Children's Hospital at Westmead, Sydney Children's Hospitals Network, Sydney, Australia
- Children's Hospital at Westmead, Sydney Children's Hospitals Network, Sydney, NSW, Australia
| | - Ruth Armstrong
- East Anglian Medical Genetics Service, Clinical Genetics, Addenbrooke's Treatment Centre, Addenbrooke's Hospital, Cambridge, UK
| | - Vera M Kalscheuer
- Max Planck Institute for Molecular Genetics, Group Development and Disease, Berlin, Germany.
| |
Collapse
|
3
|
Guarnieri FC, Pozzi D, Raimondi A, Fesce R, Valente MM, Delvecchio VS, Van Esch H, Matteoli M, Benfenati F, D'Adamo P, Valtorta F. A novel SYN1 missense mutation in non-syndromic X-linked intellectual disability affects synaptic vesicle life cycle, clustering and mobility. Hum Mol Genet 2018; 26:4699-4714. [PMID: 28973667 DOI: 10.1093/hmg/ddx352] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Accepted: 08/29/2017] [Indexed: 01/04/2023] Open
Abstract
Intellectual Disability is a common and heterogeneous disorder characterized by limitations in intellectual functioning and adaptive behaviour, whose molecular mechanisms remain largely unknown. Among the numerous genes found to be involved in the pathogenesis of intellectual disability, 10% are located on the X-chromosome. We identified a missense mutation (c.236 C > G; p.S79W) in the SYN1 gene coding for synapsin I in the MRX50 family, affected by non-syndromic X-linked intellectual disability. Synapsin I is a neuronal phosphoprotein involved in the regulation of neurotransmitter release and neuronal development. Several mutations in SYN1 have been identified in patients affected by epilepsy and/or autism. The S79W mutation segregates with the disease in the MRX50 family and all affected members display intellectual disability as sole clinical manifestation. At the protein level, the S79W Synapsin I mutation is located in the region of the B-domain involved in recognition of highly curved membranes. Expression of human S79W Synapsin I in Syn1 knockout hippocampal neurons causes aberrant accumulation of small clear vesicles in the soma, increased clustering of synaptic vesicles at presynaptic terminals and increased frequency of excitatory spontaneous release events. In addition, the presence of S79W Synapsin I strongly reduces the mobility of synaptic vesicles, with possible implications for the regulation of neurotransmitter release and synaptic plasticity. These results implicate SYN1 in the pathogenesis of non-syndromic intellectual disability, showing that alterations of synaptic vesicle trafficking are one possible cause of this disease, and suggest that distinct mutations in SYN1 may lead to distinct brain pathologies.
Collapse
Affiliation(s)
- Fabrizia C Guarnieri
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy.,San Raffaele Vita-Salute University, 20132 Milan, Italy
| | - Davide Pozzi
- Laboratory of Pharmacology and Brain Pathology, Humanitas Clinical and Research Center, 20089 Rozzano, Milan, Italy
| | - Andrea Raimondi
- Experimental Imaging Center, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Riccardo Fesce
- Centre of Neuroscience and DISTA, University of Insubria, 21100 Varese, Italy
| | - Maria M Valente
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | | | - Hilde Van Esch
- Center for Human Genetics, University Hospitals Leuven, B3000 Leuven, Belgium
| | - Michela Matteoli
- Laboratory of Pharmacology and Brain Pathology, Humanitas Clinical and Research Center, 20089 Rozzano, Milan, Italy.,CNR Institute of Neuroscience, Milan, Italy
| | - Fabio Benfenati
- Department of Experimental Medicine, University of Genova, 16132 Genova, Italy.,Center for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, 16132 Genova, Italy
| | - Patrizia D'Adamo
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Flavia Valtorta
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy.,San Raffaele Vita-Salute University, 20132 Milan, Italy
| |
Collapse
|
4
|
De novo and inherited mutations in the X-linked gene CLCN4 are associated with syndromic intellectual disability and behavior and seizure disorders in males and females. Mol Psychiatry 2018; 23:222-230. [PMID: 27550844 PMCID: PMC5794876 DOI: 10.1038/mp.2016.135] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2016] [Revised: 05/14/2016] [Accepted: 06/20/2016] [Indexed: 12/21/2022]
Abstract
Variants in CLCN4, which encodes the chloride/hydrogen ion exchanger CIC-4 prominently expressed in brain, were recently described to cause X-linked intellectual disability and epilepsy. We present detailed phenotypic information on 52 individuals from 16 families with CLCN4-related disorder: 5 affected females and 2 affected males with a de novo variant in CLCN4 (6 individuals previously unreported) and 27 affected males, 3 affected females and 15 asymptomatic female carriers from 9 families with inherited CLCN4 variants (4 families previously unreported). Intellectual disability ranged from borderline to profound. Behavioral and psychiatric disorders were common in both child- and adulthood, and included autistic features, mood disorders, obsessive-compulsive behaviors and hetero- and autoaggression. Epilepsy was common, with severity ranging from epileptic encephalopathy to well-controlled seizures. Several affected individuals showed white matter changes on cerebral neuroimaging and progressive neurological symptoms, including movement disorders and spasticity. Heterozygous females can be as severely affected as males. The variability of symptoms in females is not correlated with the X inactivation pattern studied in their blood. The mutation spectrum includes frameshift, missense and splice site variants and one single-exon deletion. All missense variants were predicted to affect CLCN4's function based on in silico tools and either segregated with the phenotype in the family or were de novo. Pathogenicity of all previously unreported missense variants was further supported by electrophysiological studies in Xenopus laevis oocytes. We compare CLCN4-related disorder with conditions related to dysfunction of other members of the CLC family.
Collapse
|
5
|
Hu H, Haas SA, Chelly J, Van Esch H, Raynaud M, de Brouwer APM, Weinert S, Froyen G, Frints SGM, Laumonnier F, Zemojtel T, Love MI, Richard H, Emde AK, Bienek M, Jensen C, Hambrock M, Fischer U, Langnick C, Feldkamp M, Wissink-Lindhout W, Lebrun N, Castelnau L, Rucci J, Montjean R, Dorseuil O, Billuart P, Stuhlmann T, Shaw M, Corbett MA, Gardner A, Willis-Owen S, Tan C, Friend KL, Belet S, van Roozendaal KEP, Jimenez-Pocquet M, Moizard MP, Ronce N, Sun R, O'Keeffe S, Chenna R, van Bömmel A, Göke J, Hackett A, Field M, Christie L, Boyle J, Haan E, Nelson J, Turner G, Baynam G, Gillessen-Kaesbach G, Müller U, Steinberger D, Budny B, Badura-Stronka M, Latos-Bieleńska A, Ousager LB, Wieacker P, Rodríguez Criado G, Bondeson ML, Annerén G, Dufke A, Cohen M, Van Maldergem L, Vincent-Delorme C, Echenne B, Simon-Bouy B, Kleefstra T, Willemsen M, Fryns JP, Devriendt K, Ullmann R, Vingron M, Wrogemann K, Wienker TF, Tzschach A, van Bokhoven H, Gecz J, Jentsch TJ, Chen W, Ropers HH, Kalscheuer VM. X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes. Mol Psychiatry 2016; 21:133-48. [PMID: 25644381 PMCID: PMC5414091 DOI: 10.1038/mp.2014.193] [Citation(s) in RCA: 208] [Impact Index Per Article: 23.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Revised: 11/17/2014] [Accepted: 12/08/2014] [Indexed: 12/27/2022]
Abstract
X-linked intellectual disability (XLID) is a clinically and genetically heterogeneous disorder. During the past two decades in excess of 100 X-chromosome ID genes have been identified. Yet, a large number of families mapping to the X-chromosome remained unresolved suggesting that more XLID genes or loci are yet to be identified. Here, we have investigated 405 unresolved families with XLID. We employed massively parallel sequencing of all X-chromosome exons in the index males. The majority of these males were previously tested negative for copy number variations and for mutations in a subset of known XLID genes by Sanger sequencing. In total, 745 X-chromosomal genes were screened. After stringent filtering, a total of 1297 non-recurrent exonic variants remained for prioritization. Co-segregation analysis of potential clinically relevant changes revealed that 80 families (20%) carried pathogenic variants in established XLID genes. In 19 families, we detected likely causative protein truncating and missense variants in 7 novel and validated XLID genes (CLCN4, CNKSR2, FRMPD4, KLHL15, LAS1L, RLIM and USP27X) and potentially deleterious variants in 2 novel candidate XLID genes (CDK16 and TAF1). We show that the CLCN4 and CNKSR2 variants impair protein functions as indicated by electrophysiological studies and altered differentiation of cultured primary neurons from Clcn4(-/-) mice or after mRNA knock-down. The newly identified and candidate XLID proteins belong to pathways and networks with established roles in cognitive function and intellectual disability in particular. We suggest that systematic sequencing of all X-chromosomal genes in a cohort of patients with genetic evidence for X-chromosome locus involvement may resolve up to 58% of Fragile X-negative cases.
Collapse
Affiliation(s)
- H Hu
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - S A Haas
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - J Chelly
- University Paris Descartes, Paris, France,Centre National de la Recherche Scientifique Unité Mixte de Recherche 8104, Institut National de la Santé et de la Recherche Médicale Unité 1016, Institut Cochin, Paris, France
| | - H Van Esch
- Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium
| | - M Raynaud
- Inserm U930 ‘Imaging and Brain', Tours, France,University François-Rabelais, Tours, France,Centre Hospitalier Régional Universitaire, Service de Génétique, Tours, France
| | - A P M de Brouwer
- Department of Human Genetics, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands
| | - S Weinert
- Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany,Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany
| | - G Froyen
- Human Genome Laboratory, VIB Center for the Biology of Disease, Leuven, Belgium,Human Genome Laboratory, Department of Human Genetics, K.U. Leuven, Leuven, Belgium
| | - S G M Frints
- Department of Clinical Genetics, Maastricht University Medical Center, azM, Maastricht, The Netherlands,School for Oncology and Developmental Biology, GROW, Maastricht University, Maastricht, The Netherlands
| | - F Laumonnier
- Inserm U930 ‘Imaging and Brain', Tours, France,University François-Rabelais, Tours, France
| | - T Zemojtel
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - M I Love
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - H Richard
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - A-K Emde
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - M Bienek
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - C Jensen
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - M Hambrock
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - U Fischer
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - C Langnick
- Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany
| | - M Feldkamp
- Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany
| | - W Wissink-Lindhout
- Department of Human Genetics, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands
| | - N Lebrun
- University Paris Descartes, Paris, France,Centre National de la Recherche Scientifique Unité Mixte de Recherche 8104, Institut National de la Santé et de la Recherche Médicale Unité 1016, Institut Cochin, Paris, France
| | - L Castelnau
- University Paris Descartes, Paris, France,Centre National de la Recherche Scientifique Unité Mixte de Recherche 8104, Institut National de la Santé et de la Recherche Médicale Unité 1016, Institut Cochin, Paris, France
| | - J Rucci
- University Paris Descartes, Paris, France,Centre National de la Recherche Scientifique Unité Mixte de Recherche 8104, Institut National de la Santé et de la Recherche Médicale Unité 1016, Institut Cochin, Paris, France
| | - R Montjean
- University Paris Descartes, Paris, France,Centre National de la Recherche Scientifique Unité Mixte de Recherche 8104, Institut National de la Santé et de la Recherche Médicale Unité 1016, Institut Cochin, Paris, France
| | - O Dorseuil
- University Paris Descartes, Paris, France,Centre National de la Recherche Scientifique Unité Mixte de Recherche 8104, Institut National de la Santé et de la Recherche Médicale Unité 1016, Institut Cochin, Paris, France
| | - P Billuart
- University Paris Descartes, Paris, France,Centre National de la Recherche Scientifique Unité Mixte de Recherche 8104, Institut National de la Santé et de la Recherche Médicale Unité 1016, Institut Cochin, Paris, France
| | - T Stuhlmann
- Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany,Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany
| | - M Shaw
- School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, SA, Australia,Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia
| | - M A Corbett
- School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, SA, Australia,Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia
| | - A Gardner
- School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, SA, Australia,Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia
| | - S Willis-Owen
- School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, SA, Australia,National Heart and Lung Institute, Imperial College London, London, UK
| | - C Tan
- School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, SA, Australia
| | - K L Friend
- SA Pathology, Women's and Children's Hospital, Adelaide, SA, Australia
| | - S Belet
- Human Genome Laboratory, VIB Center for the Biology of Disease, Leuven, Belgium,Human Genome Laboratory, Department of Human Genetics, K.U. Leuven, Leuven, Belgium
| | - K E P van Roozendaal
- Department of Clinical Genetics, Maastricht University Medical Center, azM, Maastricht, The Netherlands,School for Oncology and Developmental Biology, GROW, Maastricht University, Maastricht, The Netherlands
| | - M Jimenez-Pocquet
- Centre Hospitalier Régional Universitaire, Service de Génétique, Tours, France
| | - M-P Moizard
- Inserm U930 ‘Imaging and Brain', Tours, France,University François-Rabelais, Tours, France,Centre Hospitalier Régional Universitaire, Service de Génétique, Tours, France
| | - N Ronce
- Inserm U930 ‘Imaging and Brain', Tours, France,University François-Rabelais, Tours, France,Centre Hospitalier Régional Universitaire, Service de Génétique, Tours, France
| | - R Sun
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - S O'Keeffe
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - R Chenna
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - A van Bömmel
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - J Göke
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - A Hackett
- Genetics of Learning and Disability Service, Hunter Genetics, Waratah, NSW, Australia
| | - M Field
- Genetics of Learning and Disability Service, Hunter Genetics, Waratah, NSW, Australia
| | - L Christie
- Genetics of Learning and Disability Service, Hunter Genetics, Waratah, NSW, Australia
| | - J Boyle
- Genetics of Learning and Disability Service, Hunter Genetics, Waratah, NSW, Australia
| | - E Haan
- School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, SA, Australia,SA Pathology, Women's and Children's Hospital, Adelaide, SA, Australia
| | - J Nelson
- Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, WA, Australia
| | - G Turner
- Genetics of Learning and Disability Service, Hunter Genetics, Waratah, NSW, Australia
| | - G Baynam
- Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, WA, Australia,School of Paediatrics and Child Health, University of Western Australia, Perth, WA, Australia,Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia,Telethon Kids Institute, Perth, WA, Australia
| | | | - U Müller
- Institut für Humangenetik, Justus-Liebig-Universität Giessen, Giessen, Germany,bio.logis Center for Human Genetics, Frankfurt a. M., Germany
| | - D Steinberger
- Institut für Humangenetik, Justus-Liebig-Universität Giessen, Giessen, Germany,bio.logis Center for Human Genetics, Frankfurt a. M., Germany
| | - B Budny
- Chair and Department of Endocrinology, Metabolism and Internal Diseases, Ponzan University of Medical Sciences, Poznan, Poland
| | - M Badura-Stronka
- Chair and Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland
| | - A Latos-Bieleńska
- Chair and Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland
| | - L B Ousager
- Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
| | - P Wieacker
- Institut für Humangenetik, Universitätsklinikum Münster, Muenster, Germany
| | | | - M-L Bondeson
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | - G Annerén
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | - A Dufke
- Institut für Medizinische Genetik und Angewandte Genomik, Tübingen, Germany
| | - M Cohen
- Kinderzentrum München, München, Germany
| | - L Van Maldergem
- Centre de Génétique Humaine, Université de Franche-Comté, Besançon, France
| | - C Vincent-Delorme
- Service de Génétique, Hôpital Jeanne de Flandre CHRU de Lilles, Lille, France
| | - B Echenne
- Service de Neuro-Pédiatrie, CHU Montpellier, Montpellier, France
| | - B Simon-Bouy
- Laboratoire SESEP, Centre hospitalier de Versailles, Le Chesnay, France
| | - T Kleefstra
- Department of Human Genetics, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands
| | - M Willemsen
- Department of Human Genetics, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands
| | - J-P Fryns
- Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium
| | - K Devriendt
- Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium
| | - R Ullmann
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - M Vingron
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - K Wrogemann
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany,Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB, Canada
| | - T F Wienker
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - A Tzschach
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - H van Bokhoven
- Department of Human Genetics, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands
| | - J Gecz
- School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, SA, Australia,Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia
| | - T J Jentsch
- Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany,Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany
| | - W Chen
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany,Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany
| | - H-H Ropers
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - V M Kalscheuer
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany,Max Planck Institute for Molecular Genetics, Ihnestrasse 73, Berlin 14195, Germany. E-mail:
| |
Collapse
|
6
|
Mochel F, Missirian C, Reynaud R, Moncla A. Normal intelligence and social interactions in a male patient despite the deletion of NLGN4X and the VCX genes. Eur J Med Genet 2007; 51:68-73. [PMID: 18194880 DOI: 10.1016/j.ejmg.2007.11.002] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2007] [Accepted: 11/18/2007] [Indexed: 11/25/2022]
Abstract
Xp22.3 deletion in males can be associated with short stature (SHOX), chondrodysplasia punctata (ARSE), mental retardation (MRX49 locus), ichthyosis (STS), Kallmann syndrome (KAL1) and ocular albinism (OA1), according to the size of the deletion. Studies of terminal and interstitial deletions in male patients with a partial nullisomy of the X chromosome have led to the identification of the VCX-3A gene at the MRX49 locus on Xp22.3. The NLGN4X gene has then been identified less than 350 kb away from VCX-3A. Nonsense mutations in NLGN4X have been associated with autism and/or moderate mental retardation in males. We report a 17-year old male patient presenting with severe ichthyosis and Kallmann syndrome related to a 3.7 Mb interstitial Xp22.3 deletion, encompassing STS and KAL1 genes, respectively. However, despite the deletion of NLGN4X and all VCX genes, including VCX-3A, our patient did not manifest any learning disabilities or behavioural problems. Therefore, our case argues against a major role of NLGN4X and the VCX genes alone in cognitive development and/or communication processes.
Collapse
Affiliation(s)
- Fanny Mochel
- INSERM U679, Hôpital de la Salpêtrière, Paris, France
| | | | | | | |
Collapse
|
7
|
Kato M. A new paradigm for West syndrome based on molecular and cell biology. Epilepsy Res 2006; 70 Suppl 1:S87-95. [PMID: 16806828 DOI: 10.1016/j.eplepsyres.2006.02.008] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2005] [Revised: 01/10/2006] [Accepted: 02/06/2006] [Indexed: 02/02/2023]
Abstract
Symptomatic West syndrome has heterogeneous backgrounds. Recently, two novel genes, ARX and CDKL5, have been found to be responsible for cryptogenic West syndrome or infantile spasms. Both are located in the human chromosome Xp22 region and are mainly expressed and play roles in fetal brain. Moreover, several genes responsible for brain malformations including lissencephaly, which is frequently associated with West syndrome or infantile spasms, have been found, and the mechanisms responsible for the neural network disorders in these brain malformations are rapidly being determined. Findings of animal and in vitro studies and mutation analyses in humans are delineating the molecular and cellular basis of West syndrome. Mutations of the ARX gene controlling the development of GABAergic interneurons exhibit pleiotropic effects including lissencephaly with a strong genotype-phenotype correlation. An expansion mutation of the first polyalanine tract of ARX is more strongly related to infantile spasms than is that of the second polyalanine tract. Although the phenotype of CDKL5 mutation is similar to Rett syndrome caused by MECP2 mutation, the former is characterized by early-onset seizures and association with West syndrome. Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms. Both LIS1 and DCX participate in the development of GABAergic interneurons as well as pyramidal neurons, while ARX participates only in that of interneurons. Individuals with lissencephaly due to ARX mutation lack non-pyramidal or GABAergic interneurons. ARX is crucial for the development of GABAergic interneuron, so abnormal interneurons in patients with ARX mutation are thought to be implicated in the pathological mechanism, even though brain MRI is normal. Abnormal interneurons appear to play an essential role in the pathogenesis of West syndrome or infantile spasms, which can be considered an interneuronopathy.
Collapse
Affiliation(s)
- Mitsuhiro Kato
- Department of Pediatrics, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
| |
Collapse
|
8
|
Ma Q, Yu Y, Meng Y, Farrell J, Farrer LA, Wilcox MA. Genome-wide linkage analysis for alcohol dependence: a comparison between single-nucleotide polymorphism and microsatellite marker assays. BMC Genet 2005; 6 Suppl 1:S8. [PMID: 16451694 PMCID: PMC1866701 DOI: 10.1186/1471-2156-6-s1-s8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Both theoretical and applied studies have proven that the utility of single nucleotide polymorphism (SNP) markers in linkage analysis is more powerful and cost-effective than current microsatellite marker assays. Here we performed a whole-genome scan on 115 White, non-Hispanic families segregating for alcohol dependence, using one 10.3-cM microsatellite marker set and two SNP data sets (0.33-cM, 0.78-cM spacing). Two definitions of alcohol dependence (ALDX1 and ALDX2) were used. Our multipoint nonparametric linkage analysis found alcoholism was nominal linked to 12 genomic regions. The linkage peaks obtained by using the microsatellite marker set and the two SNP sets had a high degree of correspondence in general, but the microsatellite marker set was insufficient to detect some nominal linkage peaks. The presence of linkage disequilibrium between markers did not significantly affect the results. Across the entire genome, SNP datasets had a much higher average linkage information content (0.33 cM: 0.93, 0.78 cM: 0.91) than did microsatellite marker set (0.57). The linkage peaks obtained through two SNP datasets were very similar with some minor differences. We conclude that genome-wide linkage analysis by using approximately 5,000 SNP markers evenly distributed across the human genome is sufficient and might be more powerful than current 10-cM microsatellite marker assays.
Collapse
Affiliation(s)
- Qianli Ma
- Genetics Program, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA
- Bioinformatics Graduate Program, Boston University, 44 Cummington Street, Boston, MA 02215, USA
| | - Yi Yu
- Genetics Program, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA
- Bioinformatics Graduate Program, Boston University, 44 Cummington Street, Boston, MA 02215, USA
| | - Yan Meng
- Genetics Program, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA
- Bioinformatics Graduate Program, Boston University, 44 Cummington Street, Boston, MA 02215, USA
| | - John Farrell
- Genetics Program, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA
| | - Lindsay A Farrer
- Genetics Program, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA
| | - Marsha A Wilcox
- Genetics Program, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA
| |
Collapse
|
9
|
Abstract
X-linked mental retardation (XLMR) is a very heterogeneous condition, subdivided in two categories mainly based on clinical features: syndromic XLMR (MRXS) and non-syndromic XLMR (MRX). Although it was thought that 20-25% of mental retardation (MR) in males was caused by monogenetic X-linked factors, recent estimations are lower: in the range of 10-12%. The number of identified genes involved in XLMR has been rapidly growing in the past years. Subsequently, an increasing number of patients and families have been reported in which mutations in XLMR genes have been identified. It was observed previously, that mutations in several of XLMR genes can result in syndromic and in non-syndromic phenotypes. This observation has been confirmed for the more recently identified genes. Therefore, in this review, focus has been given on the clinical data and on phenotype-genotype correlations for those genes implicated in both non-syndromic and syndromic XLMR.
Collapse
Affiliation(s)
- T Kleefstra
- Department of Human Genetics, Radboud University Medical Center Nijmegen, the Netherlands
| | | |
Collapse
|
10
|
Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Ropers HH, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 2004; 74:552-7. [PMID: 14963808 PMCID: PMC1182268 DOI: 10.1086/382137] [Citation(s) in RCA: 535] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2003] [Accepted: 12/11/2003] [Indexed: 12/15/2022] Open
Abstract
A large French family including members affected by nonspecific X-linked mental retardation, with or without autism or pervasive developmental disorder in affected male patients, has been found to have a 2-base-pair deletion in the Neuroligin 4 gene (NLGN4) located at Xp22.33. This mutation leads to a premature stop codon in the middle of the sequence of the normal protein and is thought to suppress the transmembrane domain and sequences important for the dimerization of neuroligins that are required for proper cell-cell interaction through binding to beta-neurexins. As the neuroligins are mostly enriched at excitatory synapses, these results suggest that a defect in synaptogenesis may lead to deficits in cognitive development and communication processes. The fact that the deletion was present in both autistic and nonautistic mentally retarded males suggests that the NLGN4 gene is not only involved in autism, as previously described, but also in mental retardation, indicating that some types of autistic disorder and mental retardation may have common genetic origins.
Collapse
Affiliation(s)
- Frédéric Laumonnier
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Frédérique Bonnet-Brilhault
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Marie Gomot
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Romuald Blanc
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Albert David
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Marie-Pierre Moizard
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Martine Raynaud
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Nathalie Ronce
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Eric Lemonnier
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Patrick Calvas
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Béatrice Laudier
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Jamel Chelly
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Jean-Pierre Fryns
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Hans-Hilger Ropers
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Ben C. J. Hamel
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Christian Andres
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Catherine Barthélémy
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Claude Moraine
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Sylvain Briault
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| |
Collapse
|
11
|
Dessay S, Moizard MP, Gilardi JL, Opitz JM, Middleton-Price H, Pembrey M, Moraine C, Briault S. FG syndrome: linkage analysis in two families supporting a new gene localization at Xp22.3 [FGS3]. AMERICAN JOURNAL OF MEDICAL GENETICS 2002; 112:6-11. [PMID: 12239712 DOI: 10.1002/ajmg.10546] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
FG syndrome (OMIM 305450) is an X-linked condition comprising mental retardation, congenital hypotonia, constipation or anal malformations, and a distinctive appearance with disproportionately large head, tall and broad forehead, cowlicks and telecanthus. In a first linkage analysis carried out on 10 families, we demonstrated heterogeneity and assigned one gene [FGS1] to region Xq12-q21.31 [Briault et al., 1997: Am J Med Genet 73:87-90] corroborated by Graham et al. [1998: Am J Med Genet 80:145-156]. Heterogeneity was supported by the study of one family with apparent FG syndrome co-segregating with an inversion of X chromosome [inv(X)(q11q28)] ([FGS2], OMIM 300321) [Briault et al., 1999: Am J Med Genet 86:112-114 and Briault et al., 2000: Am J Med Genet 95:178-181]. We present the results of a new linkage analysis carried out on two families with FG syndrome. The two earlier known loci for FG syndrome, FGS1 and FGS2 (Xq11 or Xq28) were excluded by multipoint analysis of both families. Linkage was found, however, with locus DXS1060 suggesting that a third FG locus might be located at Xp22.3. In this region, two potential candidate genes, VCX-A and PRKX, were excluded by sequence analysis of the coding region in patients of the two reported FG families. The search for new candidate genes is in progress.
Collapse
Affiliation(s)
- Sabine Dessay
- Service de Génétique, CHU Bretonneau, Tours, France.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Fukami M, Kirsch S, Schiller S, Richter A, Benes V, Franco B, Muroya K, Rao E, Merker S, Niesler B, Ballabio A, Ansorge W, Ogata T, Rappold GA. A member of a gene family on Xp22.3, VCX-A, is deleted in patients with X-linked nonspecific mental retardation. Am J Hum Genet 2000; 67:563-73. [PMID: 10903929 PMCID: PMC1287516 DOI: 10.1086/303047] [Citation(s) in RCA: 79] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2000] [Accepted: 06/23/2000] [Indexed: 11/03/2022] Open
Abstract
X-linked nonspecific mental retardation (MRX) has a frequency of 0.15% in the male population and is caused by defects in several different genes on the human X chromosome. Genotype-phenotype correlations in male patients with a partial nullisomy of the X chromosome have suggested that at least one locus involved in MRX is on Xp22.3. Previous deletion mapping has shown that this gene resides between markers DXS1060 and DXS1139, a region encompassing approximately 1.5 Mb of DNA. Analyzing the DNA of 15 males with Xp deletions, we were able to narrow this MRX critical interval to approximately 15 kb of DNA. Only one gene, VCX-A (variably charged, X chromosome mRNA on CRI-S232A), was shown to reside in this interval. Because of a variable number of tandem 30-bp repeats in the VCX-A gene, the size of the predicted protein is 186-226 amino acids. VCX-A belongs to a gene family containing at least four nearly identical paralogues on Xp22.3 (VCX-A, -B, -B1, and -C) and two on Yq11.2 (VCY-D, VCY-E), suggesting that the X and Y copies were created by duplication events. We have found that VCX-A is retained in all patients with normal intelligence and is deleted in all patients with mental retardation. There is no correlation between the presence or absence of VCX-B1, -B, and VCX-C and mental status in our patients. These results suggest that VCX-A is sufficient to maintain normal mental development.
Collapse
Affiliation(s)
- Maki Fukami
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Stefan Kirsch
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Simone Schiller
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Alexandra Richter
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Vladimir Benes
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Brunella Franco
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Koji Muroya
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Ercole Rao
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Sabine Merker
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Beate Niesler
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Andrea Ballabio
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Wilhelm Ansorge
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Tsutomu Ogata
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| | - Gudrun A. Rappold
- Institute of Human Genetics, University of Heidelberg, and European Molecular Biology Laboratory, Heidelberg; Telethon Institute of Genetics and Medicine, Milan; and Department of Pediatrics, Keio University, Tokyo
| |
Collapse
|
13
|
Matsuo M, Muroya K, Nanao K, Hasegawa Y, Terasaki H, Kosaki K, Ogata T. Mother and daughter with 45,X/46,X,r(X)(p22.3q28) and mental retardation: Analysis of the x-inactivation patterns. ACTA ACUST UNITED AC 2000. [DOI: 10.1002/(sici)1096-8628(20000410)91:4<267::aid-ajmg5>3.0.co;2-j] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
14
|
Baralle D, Willatt L, Shears D. L�ri-Weill syndrome associated with a pseudodicentric X;Y translocation chromosome and skewed X-inactivation: Implications for genetic counselling. ACTA ACUST UNITED AC 2000. [DOI: 10.1002/1096-8628(20001211)95:4<391::aid-ajmg17>3.0.co;2-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
15
|
Spranger S, Schiller S, Jauch A, Wolff K, Rauterberg-Ruland I, Hager D, Tariverdian G, Tröger J, Rappold G. Léri-Weill syndrome as part of a contiguous gene syndrome at Xp22.3. AMERICAN JOURNAL OF MEDICAL GENETICS 1999; 83:367-71. [PMID: 10232745 DOI: 10.1002/(sici)1096-8628(19990423)83:5<367::aid-ajmg5>3.0.co;2-k] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
We report on a mother and her 5-year old son, both with a terminal deletion of the short arm of the X chromosome. By molecular genetic analysis the breakpoint was located distal to steroid sulfatase gene. The boy manifested, due to nullisomy of this region, short stature (SHOX), chondrodysplasia punctata (ARSE), and mental retardation (putative mental retardation gene MRX 49). Short stature is present in mother and son, but both also had bilateral Madelung deformity, a key finding in the Léri-Weill syndrome. We discuss the phenotype in relationship to hitherto published cases with chromosomal aberrations and contiguous gene syndromes of Xp22.3.
Collapse
Affiliation(s)
- S Spranger
- Center for Human Genetics and Genetic Counseling, University of Bremen, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
|